Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regencell Bioscience Holdings Limited - Ordinary Shares
(NQ:
RGC
)
30.03
+1.08 (+3.73%)
Streaming Delayed Price
Updated: 9:58 AM EDT, Apr 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Regencell Bioscience Holdings Limited - Ordinary Shares
Kaplan Fox Encourages Investors of Regencell Bioscience Holdings Limited (NASDAQ: RGC) to Contact the Firm Before Lead Plaintiff Deadline on June 23, 2026
Today 10:00 EDT
NEW YORK, NY - April 30, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited (“Regencell” or the...
Via
TheNewswire.com
Topics
Law Enforcement
Lawsuit
Kaplan Fox Encourages Investors of Regencell Bioscience Holdings Limited (NASDAQ: RGC) to Contact the Firm Before Lead Plaintiff Deadline on June 23, 2026
Today 10:00 EDT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Law Enforcement
Lawsuit
Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Today 9:00 EDT
From
Law Offices of Howard G. Smith
Via
Business Wire
Kaplan Fox Alerts Regencell Bioscience Holdings Limited (RGC) Investors of June 23, 2026 Lead Plaintiff Deadline in Securities Class Action Case
April 29, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Law Enforcement
Lawsuit
Kaplan Fox Alerts Regencell Bioscience Holdings Limited (RGC) Investors of June 23, 2026 Lead Plaintiff Deadline in Securities Class Action Case
April 29, 2026
NEW YORK, NY - April 29, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited (“Regencell” or the...
Via
TheNewswire.com
Topics
Law Enforcement
Lawsuit
Securities Fraud Investigation Into Regencell Bioscience Holdings Limited (RGC) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
April 29, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers – RGC
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit with the Schall Law Firm
April 28, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGC
April 27, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
REGENCELL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Regencell Bioscience Holdings Limited and Encourages Investors to Contact the Firm
April 27, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
April 27, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
Investor Notice: Robbins LLP Informs Investors of the Regencell Bioscience Holdings Limited Class Action
April 24, 2026
From
Robbins LLP
Via
Business Wire
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
March 03, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
January 08, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
December 11, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell, Beyond Meat, Alvotech, and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
November 22, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Regencell, Beyond Meat, Alvotech, and Camping World and Encourages Investors to Contact the Firm
November 12, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial
September 12, 2022
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
May 18, 2022
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
May 16, 2022
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network
March 01, 2022
LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings...
From
Stock News Now
Via
AccessWire
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial
February 16, 2022
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors
December 13, 2021
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO
November 22, 2021
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index
November 22, 2021
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment
September 02, 2021
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter’s Over-Allotment Option
August 20, 2021
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Holdings Limited Releases CEO Letter to Shareholders
August 05, 2021
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering
July 20, 2021
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering
July 15, 2021
From
Regencell Bioscience Holdings Limited
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.